SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Attention centers on CRISPR Therapeutics CTX310 clinical data and other pipeline readouts, with traders debating whether encouraging results can shift sentiment toward its in-vivo gene-editing and autoimmune programs. Optimism about the catalysts and Casgevys commercial ramp is tempered by frustration that the stock has remained range-bound and may not respond to positive developments.

Starbucks Corp. engages in the production, marketing, and retailing of specialty coffee. It operates through the following segments: North America, International, and Channel Development. The North America segment focuses on the United States and Canada. The International segment is involved in China, Japan, Asia Pacific, Europe, Middle East, Africa, Latin America, and Caribbean. The Channel Development segment includes roasted whole bean and ground coffees, Seattle’s Best Coffee, and Teavana-branded single-serve products. The company was founded by Jerry Baldwin and Howard D. Schultz on November 4, 1985, and is headquartered in Seattle, WA.

Starbucks Corp.

Starbucks Corp

Starbucks quarterly results sparked debate after stronger-than-expected earnings and comparable sales were offset by a revenue miss, with the China restructuring weighing on reported sales and the stocks reaction remaining subdued. Bulls point to improving U.S. traffic and the turnaround outlook, while bears question the valuation and whether growth can justify it.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could decline sharply through 2027 has weighed on CRMD, intensifying concerns about pricing and revenue from its flagship product. Traders disagree on how decisive the warning is: some view DaVitas estimates as preliminary and point to CMS reimbursement and adoption as offsets, while others see lasting pressure on the business outlook.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Takeover speculation has fueled attention after reports that Lundbeck explored acquiring Xeris, though the company said it is not for sale and traders disagree on whether a deal is likely. The discussion also centers on upcoming quarterly results and the longer-term potential of Recorlev growth and XP-8121s planned Phase 3 program.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Ciscos decline is being tied to an analyst price-target cut amid concerns that networking growth may be peaking and the stocks valuation could compress; the firm kept its rating unchanged. Traders are split between calling the selloff an overreaction given AI-networking demand and seeing continued technical weakness.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Traders are split on Disneys choppy, range-bound trading, with bullish breakout and call-positioning talk countered by bearish bets on a pullback. Some posts also react negatively to allegations involving the company, but the discussion does not establish them as a confirmed market catalyst.

BNB (BNB) is a cryptocurrency . BNB has a current supply of 131,511,387.69. The last known price of BNB is 703.59425696 USD and is up 0.47 over the last 24 hours. It is currently trading on 3523 active market(s) with $2,735,089,335.64 traded over the last 24 hours. More information can be found at https://bnbchain.org/en.

Binance

A reported multibillion-dollar Binance security breach is driving attention, with traders focused on suspended withdrawals and concerns about exchange security and customer funds. The community debates whether Binance can cover the losses and whether BNBs limited decline understates the risk; claims of an inside job or specific perpetrators remain speculation.

Invesco Exchange-Traded Fund Trust - Invesco S&P 500 Equal Weight ETF

Invesco S&P 500 Equal Weight ETF

RSP is drawing attention as a gauge of market breadth and the rotation between mega-cap tech and the broader S&P 500: traders have highlighted periods of equal-weight outperformance as participation widens beyond AI and tech leaders. The reaction is mixed, with some viewing the rotation as healthy broadening and others warning that recent RSP weakness signals deteriorating breadth and renewed concentration in a few large stocks.

Pudgy Penguins (PENGU) is a cryptocurrency launched in 2024and operates on the Solana platform. Pudgy Penguins has a current supply of 76,724,221,264.3 with 62,860,396,090.04 in circulation. The last known price of Pudgy Penguins is 0.00754361 USD and is up 6.59 over the last 24 hours. It is currently trading on 540 active market(s) with $130,377,930.32 traded over the last 24 hours. More information can be found at https://www.pengu.pudgypenguins.com.

Pudgy Penguins

PENGU is drawing attention around its pullback and attempts to hold a technical support zone, with traders debating whether it can rebound or break lower. Dip buyers point to possible support and broader crypto-market recovery, while bears cite persistent selling, weak momentum and a lack of fresh catalysts.

Barrick Mining Corp. engages in the production and sale of gold, copper, and related activities. It also provides exploration and mining development. It operates through the following business segments: Carlin, Cortez, Turquoise Ridge, Pueblo Viejo, Loulo-Gounkoto, Kibali, Veladero, North Mara, Bulyanhulu, and Other Mines. The company was founded by Peter D. Munk in 1983 and is headquartered in Toronto, Canada.

Barrick Mining Corp.

Barrick Mining Corp

Barrick is drawing attention as its shares and the wider mining sector face pressure, with repeated technical analysis suggesting the correction may not be over. Traders are divided between expecting further weakness and treating the pullback as an opportunity to add, while gold-price and interest-rate concerns weigh on near-term sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of +33.33% and -5.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036

Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036...

Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -125.56% and -5.20%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Akebia Therapeutics (AKBA) Expected to Announce Quarterly Earnings on Thursday

Akebia Therapeutics (NASDAQ:AKBA) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-akebia-therapeutics-inc-stock...

United Therapeutics (UTHR) Misses Q1 Earnings and Revenue Estimates

United Therapeutics (UTHR) delivered earnings and revenue surprises of -13.58% and -2.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Q32 Bio Gears Up to Report Q1 Earnings: What's in the Cards?

QTTB heads into Q1 earnings with investors eyeing bempikibart updates, as the SIGNAL-AA study progresses with data due in mid-2026.

Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of +64.71% and +29.20%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Are Options Traders Betting on a Big Move in Akebia Therapeutics Stock?

Investors need to pay close attention to AKBA stock based on the movements in the options market lately. 

New Strong Sell Stocks for April 28th

EADSY, AKBA and AMTB have been added to the Zacks Rank #5 (Strong Sell) List on April 28, 2026.

Akebia Therapeutics (NASDAQ:AKBA) Shares Cross Below Two Hundred Day Moving Average   - Here's What Happened

Akebia Therapeutics (NASDAQ:AKBA) Stock Crosses Below 200-Day Moving Average - Should You Sell...

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vafseo. The company was founded by Joseph H. Gardner, John M. Rice Jr., Michael E. Pape, Josh P. Fairbank, and Robert A. Shalwitz on February 27, 2007 and is headquartered in Cambridge, MA.

Akebia Therapeutics Inc.

AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction

Equity

Extremely Bullish Sentiment

<ul class="summary-bullets"><li>Enrollment is also underway for the company’s study of its other experimental therapy praliciguat in focal segmental glomerulosclerosis (FSGS).</li><li>In 2026, the company expects a significant revenue growth for Vafseo through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates.</li><li>The company ended Q4 with cash and cash equivalents of about $184.8 million, which it expects to be sufficient to fund current operating plan for at least two years.</li></ul>&nbsp;Shares of Akebia Therapeutics Inc (AKBA) rose 7% on Thursday after the company announced that it expects significant revenue growth for its approved anemia medicine Vafseo in 2026 while it also advances its clinical pipeline.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.akebia.com/news-releases/news-release-details/akebia-therapeutics-reports-fourth-quarter-and-full-year-2025">said</a> on Thursday that it now expects its mid-stage trial of AKB-097 in rare kidney diseases to start in the second half of 2026, with initial data expected in 2027. Akebia acquired the experimental drug from Q32 Bio in November. The company will explore the drug in IgA nephropathy, lupus nephritis and C3 glomerulopathy, it said.Enrollment is also underway for the company’s study of its other experimental therapy praliciguat in focal segmental glomerulosclerosis (FSGS). Target enrollment for the trial is approximately 60 patients.<h2 class="st-heading-2">Future Of FDA-Approved Medicines</h2>Akebia has two medicines approved by the U.S. Food and Drug Administration including <a href="https://stocktwits.com/news-articles/markets/equity/akebia-therapeutics-stock-slumps-after-fda-meeting-ends-without-path-forward-for-vafseo-label-expansion/cLGZtPhR3wx">Vafseo </a>for the treatment of anemia due to chronic kidney disease (CKD) in dialysis patients. In 2026, the company expects a significant revenue growth for Vafseo through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates.“Vafseo commercial trends are showing marked improvement in early 2026... Patient access to Vafseo therapy now stands at 290,000 patients, and early data points to improved patient adherence rates, which we believe are enhanced as a result of dialysis organizations deciding to implement observed dosing protocols. These dynamics, along with the building evidence of clinical differentiation, are expected to drive significant Vafseo revenue growth in 2026 and beyond…, ” said CEO John P. Butler.<h2 class="st-heading-2">Q4 Numbers</h2>For the fourth quarter, the company reported net product revenues of $54.3 million, owing to a quarter-on-quarter increase in prescribers for Vafseo which was launched in the U.S. in Jan. 2025 and an increase in sales volume for Auryxia. Analysts on average were expecting the company to report revenue of $46.09 million.Net loss per share for the period came in at $0.05, compared to a loss of $0.10 in the corresponding quarter of 2024, but above an analyst estimate of a loss of $0.04.The company ended the quarter with cash and cash equivalents of about $184.8 million, which it expects to be sufficient to fund current operating plan for at least two years.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AKBA stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.A Stocktwits user highlighted the several potential catalysts for the stock including accelerating adoption for Vafseo and cash hoard.<stembedurl>https://www.stocktwits.com/ROCKET123/message/645988666</stembedurl>Another voiced hopes for stock as much as doubling “sooner or later.”<stembedurl>https://www.stocktwits.com/Andi77/message/645980832</stembedurl><a href="https://stocktwits.com/symbol/AKBA">AKBA stock</a> has fallen 28% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nvda-stock-falls-michael-burry-says-nvidia-purchase-commitments-akin-to-cisco-dot-com-bubble/cZTGi6FRIRb">Michael Burry Warns Nvidia’s ‘Purchase Commitments’ Akin To Cisco At The Top Of Dot-Com Bubble — NVDA Stock Falls 5%</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Akebia Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

The company said on Thursday that it now expects its mid-stage trial of AKB-097 in rare kidney diseases to start in the second half of 2026, with initial data expected in 2027.

Vanguard Total Stock Market ETF

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$0.7065
Prev Close	$0.7422
Open	$0.721
Dividend Yield	0.00%
50-Day Moving Average	$0.8461
Beta	1.31
Avg. Volume	6.94M
PE Ratio	-6.36

52-Week High	$2.22
52-Week Low	$0.5421
Market Capitalization	$195.78M
EPS (Annual)	-$0.0208
Price to Book	7.67
Revenue Per Employee	$1.22M

Feed

News

Sentiment

Earnings

Fundamentals

Info

AKBA Fundamentals